Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples.

Tropical biomedicine·2026
Same author

Over-prescription of short-acting β<sub>2</sub>-agonists for asthma in South Africa: Results from the SABINA III study.

African journal of thoracic and critical care medicine·2023
Same author

Flower cells in patient with HTLV1 associated adult T-cell leukaemia/lymphoma.

QJM : monthly journal of the Association of Physicians·2019
Same author

Associations of pain and depression with marital status in patients diagnosed with Parkinson's disease.

Acta neurologica Scandinavica·2015
Same author

Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).

Journal of human hypertension·2015
Same author

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.

Diabetes, obesity & metabolism·2014

関連する実験動画

Updated: Jul 1, 2026

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart
07:59

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart

Published on: June 20, 2017

慢性心不全におけるプラズマエンドセリン

J J McMurray1, S G Ray, I Abdullah

  • 1Department of Cardiology, Western Infirmary, Glasgow, UK.

Circulation
|April 1, 1992
PubMed
まとめ

慢性心不全 (CHF) の患者は,強力な血管圧縮性ペプチドである循環中のエンドセリンのレベルが上昇しています. CHFにおけるこれらのエンドセリン濃度の上昇は,疾患の病理生理学において重要な役割を果たす可能性があります.

科学分野:

  • 心血管生理学 心血管の生理学
  • エンドクリノロジー エンドクリノロジー
  • 神経ペプチド研究 神経ペプチドの研究

背景:

  • エンドセリン (endothelins) は,血管圧縮性特性で知られている,新たに発見されたペプチドです.
  • 慢性心不全 (CHF) は,外周動脈と腎臓の血管収縮と関連しています.

研究 の 目的:

  • 慢性心不全 (CHF) と診断された患者におけるプラズマのエンドセリンのような免疫反応性のレベルを調査する.

主な方法:

  • 重度のCHFの患者および健康なボランティアの周周周静脈プラズマエンドセリン濃度の測定.
  • 運動中のエンドセリン濃度の評価.
  • 血の心房ナトリウレティック因子,血清尿素,血清クレアチニンとの相関分析.
  • 腎臓エンドセリン抽出の評価.

主要な成果:

  • 重度のCHFの患者は,健康な対照群 (6.4 +/- 0.3 pmol/l) と比較して,プラズマエンドセリン濃度 (12.4 +/- 0.6 pmol/l) が著しく高かった.
  • 血のエンドセリンの濃度は,両方のグループで運動によって変化しませんでした.
  • プラズマエンドセリンと心房ナトリウレティック因子,尿素,またはクレアチニンの間の有意な相関は,CHFの患者では見つかりませんでした.

さらに関連する動画

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

関連する実験動画

Last Updated: Jul 1, 2026

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart
07:59

The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart

Published on: June 20, 2017

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

  • CHFの患者では,エンドセリンの重要な腎臓抽出が観察されました.

    • 結論:

    • 5~40 pmol/lの範囲内の循環中のエンドセリンの濃度は,血管活性であることが示唆されています.
    • CHFの患者で検出されたエンドセリン濃度の上昇は,この症候群の病理生理学的な意味を持つ可能性が高い.